JPH0220614B2 - - Google Patents

Info

Publication number
JPH0220614B2
JPH0220614B2 JP4607381A JP4607381A JPH0220614B2 JP H0220614 B2 JPH0220614 B2 JP H0220614B2 JP 4607381 A JP4607381 A JP 4607381A JP 4607381 A JP4607381 A JP 4607381A JP H0220614 B2 JPH0220614 B2 JP H0220614B2
Authority
JP
Japan
Prior art keywords
sporozoites
plasma
chickens
sample
chicken
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP4607381A
Other languages
Japanese (ja)
Other versions
JPS57159720A (en
Inventor
Kenji Shibata
Hisako Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nisshin Seifun Group Inc
Original Assignee
Nisshin Seifun Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nisshin Seifun Group Inc filed Critical Nisshin Seifun Group Inc
Priority to JP4607381A priority Critical patent/JPS57159720A/en
Publication of JPS57159720A publication Critical patent/JPS57159720A/en
Publication of JPH0220614B2 publication Critical patent/JPH0220614B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明はロイコチトゾーン・カウレリによつて
起る鶏ロイコチトゾーン症を免疫的に予防し得る
抗ロイコチトゾーン剤の接種方法に関する。 ロイコチトゾーン・カウレリの感染によつて起
るロイコチトゾーン症は日本、韓国、台湾、フイ
リピンをも含めて東南アジア地域の各国にかけて
広く分布している。これに感染した鶏は喀血、出
血、貧血、緑便などの症状を呈し、予防をしてい
ない場合または症状が重い場合には斃死すること
も少なくない。そして斃死に至らなくとも発育遅
延、産卵の停止もしくは減少などが起こるためロ
イコチトゾーン症は養鶏家にとつて被害の大きい
問題である。 従来、かかるロイコチトゾーン症の予防として
薬剤の投与が行われている。しかしながら薬剤の
投与による予防法は薬剤の耐性獲得による効果の
減退、薬剤の鶏肉や鶏卵を通しての人体への移行
などの問題があつた。 本発明者らは前記問題を解決すべく研究を行つ
た結果、鶏ロイコチトゾーン症に初めて感染した
鶏の感染後約10〜15日目の血液特に血漿を鶏の総
排泄腔より接種することにより鶏ロイコチトゾー
ン症を予防し得ることを見い出した。この場合そ
の血液中には原虫の代謝産物たる蛋白抗原が含有
されており、従つてこのような抗原含有画分例え
ば血漿も有効であることが判つている。本発明で
いう血漿は、ロイコチトゾーン・カウレリに感染
したことのない鶏にロイコチトゾーン・カウレリ
のスポロゾイトを1羽当り3000個の割合で静脈内
感染させ、感染後10〜15日目(特に13〜14日目の
ものが好ましい)採血して血漿を採ることにより
得られる。これを本発明においては活性物質を鶏
の総排泄腔に接種することが肝要である。総排泄
腔に接種する具体的方法としては鶏の肛門に点滴
するか、注入するか、スプレーをするなどの方法
が挙げられる。血漿の場合の接種量は鶏1羽当り
約0.01ml以上が好ましい。 また、本発明の活性物質に他の疾病の免疫的抗
原を混合して総排泄腔に接種することができ、例
えば鶏コクシジウムのスポロゾイト、ニユーカツ
スル病のワクチン、大腸菌などがあげられる。 本発明による接種法を用いれば副作用を起こす
ことなく鶏ロイコチトゾーン症を予防し得る。 例 1 初生鶏(レイヤー専用種シエーバー)10羽の肛
門に0日令において下記に示す試料をたらす。別
の初生鶏(レイヤー専用種シエーバー)10羽を用
意し、0,1,2,3および4日令において1日
1回下記に示す試料をたらす。次いでこれらの鶏
に38日令において1羽当り2000個のロイコチトゾ
ーン・カウレリのスポロゾイトを静内投与してロ
イコチトゾーン症に感染させる。対照は試料を接
種せずに感染のみ行つたものである。感染後24日
目までの斃死率、食下量および増体重を観察し
た。結果は表1に示す。 試料および接種方法 本発明(1):血漿を0日令時に初生鶏の総排泄腔
に1羽当り1滴(約0.03ml)たらす。 本発明:血漿を0,1,2,3および4日令時
に毎日1回初生鶏の総排泄腔に1羽当り1滴(約
0.03ml)ずつたらす。 試料に用いた血漿の調製法は以下のように行つ
た。ロイコチトゾーン・カウレリに感染したこと
のない70日令の鶏にロイコチトゾーン・カウレリ
のスポロゾイトを1羽当り3000個で静脈内接種
し、感染後13日目にヘパリンを用いて心臓穿刺し
て採血をし、3000rpm10分間遠心分離して上清す
なわち血漿〔本発明(1)および(2)として使用〕を集
収した。
The present invention relates to a method for inoculating an anti-leucocytozoon agent capable of immunologically preventing chicken leucocytozoonosis caused by Leucocytozoon cauleri. Leukocytozoonosis, caused by infection with Leucocytozoon cauleri, is widely distributed throughout the countries of Southeast Asia, including Japan, South Korea, Taiwan, and the Philippines. Chickens infected with this virus exhibit symptoms such as hemoptysis, bleeding, anemia, and green stools, and often die if preventive measures are not taken or if the symptoms are severe. Even if it does not lead to mortality, leukocytozoonosis is a serious problem for poultry farmers because it causes growth retardation and halts or decreases in egg production. Conventionally, drugs have been administered to prevent such leukocytozoonosis. However, preventive methods that involve administering drugs have had problems, such as decreased effectiveness due to the acquisition of drug resistance, and the transfer of drugs to the human body through chicken meat and chicken eggs. As a result of research conducted by the present inventors to solve the above-mentioned problem, we found that blood, particularly plasma, about 10 to 15 days after infection from chickens infected with avian leukocytozoonosis for the first time was inoculated from the cloaca of chickens. We found that chicken leukocytozoonosis can be prevented by using this method. In this case, the blood contains protein antigens that are metabolites of the protozoa, and therefore, such antigen-containing fractions, such as plasma, are also known to be effective. The plasma referred to in the present invention is obtained by intravenously infecting chickens that have never been infected with Leukocytozoon cauleri with Leukocytozoon cauleri sporozoites at a rate of 3,000 sporozoites per bird, and on the 10th to 15th day after infection (particularly (Preferably on the 13th to 14th day) Obtained by collecting blood and plasma. In the present invention, it is important to inoculate the active substance into the cloaca of chickens. Specific methods for inoculating the cloaca include dripping, injecting, and spraying into the chicken's anus. In the case of plasma, the amount of inoculation is preferably about 0.01 ml or more per chicken. In addition, the active substance of the present invention can be mixed with immunogenic antigens of other diseases and inoculated into the cloaca, such as chicken coccidia sporozoites, Newkat's disease vaccine, and Escherichia coli. By using the inoculation method according to the present invention, chicken leukocytozoonosis can be prevented without causing side effects. Example 1 Drop the following sample into the anus of 10 day old chickens (layer-specific shaver) at 0 days of age. Prepare another 10 day old chickens (layer-specific shaver) and feed them the following samples once a day at 0, 1, 2, 3, and 4 days of age. These chickens are then infected with leucocytozoonosis by intravenously administering 2000 Leukocytozoon cauleri sporozoites per bird at 38 days of age. As a control, only infection was performed without inoculating the sample. Mortality rate, food intake, and weight gain were observed up to 24 days after infection. The results are shown in Table 1. Sample and inoculation method Present invention (1): One drop (approximately 0.03 ml) of plasma is placed per chicken into the cloaca of day-old chickens at 0 days of age. Invention: Plasma is added to the cloaca of day-old chickens once daily at 0, 1, 2, 3 and 4 days of age, 1 drop per chicken (approx.
0.03ml). The plasma used as a sample was prepared as follows. Chickens 70 days old and never infected with Leucocytozoon cauleri were inoculated intravenously with 3,000 Leucocytozoon cauleri sporozoites per bird, and 13 days after infection, they were subjected to cardiac puncture using heparin. Blood was collected and centrifuged at 3000 rpm for 10 minutes to collect the supernatant, that is, plasma [used in the present invention (1) and (2)].

【表】 の1日1羽当りの平均。
例 2 スポロゾイト投与日令と投与個数をそれぞれ22
目令および1000個とした以外は例1に準じた。結
果は表2に示す。 試料および接種方法 本発明(3):血漿を0日令の鶏の総排泄腔に1羽
当り1滴(約0.03ml)たらす。 本発明(4):血漿を0,1,2,3および4日令
時に毎日1回鶏の総排泄腔に1羽当り1滴(約
0.03ml)ずつたらす。 試料に用いた血漿の調製法は下記のとおりであ
る。ロイコチトゾーン・カウレリに感染したこと
のない48日令の鶏にロイコチトゾーン・カウレリ
のスポロゾイトを1羽当り2000個で静脈内接種
し、感染後14日目に心臓穿刺して採血をし、血清
〔本発明(3)および(4)として使用〕を集収した。
[Table] Average per bird per day.
Example 2 The date of sporozoite administration and the number of sporozoites administered are 22 each.
The procedure was as in Example 1 except for the target size and 1000 pieces. The results are shown in Table 2. Sample and inoculation method Present invention (3): One drop (approximately 0.03 ml) of plasma is placed per chicken into the cloaca of 0-day-old chickens. Invention (4): Plasma is applied to the cloaca of chickens once a day at 0, 1, 2, 3 and 4 days of age, 1 drop per chicken (approx.
0.03ml). The method for preparing plasma used as a sample is as follows. 48-day-old chickens that had never been infected with Leucocytozoon cauleri were intravenously inoculated with 2,000 Leucocytozoon cauleri sporozoites per bird, and blood was collected by cardiac puncture on the 14th day after infection. Serum [used as present invention (3) and (4)] was collected.

【表】 の1日1羽当りの平均。
例 3 初生の鶏(レイヤー専用種シエーバー)10羽の
肛門に下記に示す試料を1羽当り1滴(約0.03
ml)たらした。 試料(1):アイメリア・テネラのスポロゾイト
330000個を含むPBS(−)溶液0.5mlと供試血漿
0.5mlとを混合したもの 試料(2):アイメリア・ブルネツテイのスポロゾ
イト330000個を含むPBS(−)溶液0.5mlと供試血
漿0.5mlとを混合したもの 試料(3):大腸菌浮遊液0.5mlと供試血漿0.5mlと
を混合したもの 試料(4):ニユーカツスル病生ワクチン0.5ml
(33ドーズ)と供試血漿0.5mlとを混合したもの 試料(5):アイメリア・テネラのスポロゾイト
330000個を含むPBS(−)溶液0.2mlとアイメリ
ア・ブルネツテイのスポロゾイト330000個を含む
PBS(−)溶液0.2mlと大腸菌浮遊液0.2mlとニユ
ーカツスル病生ワクチン0.2ml(33ドーズ)と供
試血漿0.2mlとを混合したもの 試料(1),(2),(3),(4)および(5)に用いた供試血
漿、アイメリア・テネラのスポロゾイト、アイメ
リア・ブルネツテイのスポロゾイト、大腸菌浮遊
液およびニユーカツスル病生ワクチンの調製法は
下記のとおりである。 供試血漿は例1と同じ方法で調製した。 試料(1)および(5)に用いたアイメリア・テネラの
スポロゾイトの調製は次のとおりである。 アイメリア・テネラの成熟オーシストを経口投
与した鶏の糞、盲腸壁および盲腸内容物を集め、
3%重クロム酸カリウム溶液に浮遊せしめそして
28℃において2日間培養した。得られた成熟オー
シストを含む溶液を遠心分離(3000rpm、10分
間)しそして沈澱を集める。次いでこの沈澱を水
で洗浄し且つ飽和食塩水を添加する。この溶液を
遠心分離(3000rpm、10分間)し、上澄をとり、
この上澄を水で希釈し、希釈液を更に遠心分離
(1000rpm、3分間)しそして沈澱を集める。こ
の沈澱はほとんどオーシストのみよりなる。前記
オーシストに水および5%の次亜塩素酸ナトリウ
ム液を加え且つ15分間放置した後、遠心分離
(2000rpm、3分間)を行う。得られた沈澱を水
で洗浄し、次いでホモジナイザーで磨砕する。こ
の磨砕物はほとんどスポロゾイトよりなる。この
スポロゾイトに5%鶏胆汁および0.25%トリプシ
ンPBS(−)溶液を加えそして40℃の温浴中でお
よび1.5時間消化せしめる。得られた消化液を遠
心分離して沈澱を集め、そしてこの沈澱をPBS
(−)溶液で洗浄する。このものはほとんどスポ
ロゾイトよりなる。これにPBS(−)溶液を加え
た。 試料(2)および(5)で用いたアイメリア・ブルネツ
テイのスポロゾイトは上記のアイメリア・テネラ
のスポロゾイト調製法に準じて行なう。ただしア
イメリア・テネラの代わりに、アイメリア・ブル
ネツテイを使用する。 試料(3)および(5)で用いた大腸菌の調製法は次の
ようである。鶏の大腸菌性敗血症の肝臓より分離
した大菌をハート・インフユージヨンブイヨン
(Difco Laboratory社製)を用いて37℃にて培養
した。18時間培養した後、10000rpmにて20分間
遠心分離を行い、大腸菌の湿菌体を得る。これに
大腸菌が1×1011個になるようにPBS(−)溶液
の所要量に懸濁せしめて大腸菌浮遊液とした。 試料(4)および(5)で用いたニユーカツスル病生ワ
クチンの調製法は化学及血清療法研究所製のニユ
ーカツスル病生ワクチンの溶解用液の所定量中に
乾燥予防液を33ドーズ分になるように溶解して調
製した。 前記試料(1)〜(5)のいずれを使用した場合にもロ
イコチトゾーン症の予防に支障はなかつた。
[Table] Average per bird per day.
Example 3 Apply one drop of the sample shown below (approximately 0.03
ml). Sample (1): Eimeria tenella sporozoites
0.5ml of PBS(-) solution containing 330,000 cells and sample plasma
Sample (2): A mixture of 0.5 ml of PBS (-) solution containing 330,000 sporozoites of Eimeria brunetsutei and 0.5 ml of sample plasma. Sample (3): A mixture of 0.5 ml of E. coli suspension and 0.5 ml of E. coli suspension. Mixed with 0.5ml of test plasma Sample (4): Newatus disease live vaccine 0.5ml
(33 doses) mixed with 0.5 ml of sample plasma Sample (5): Eimeria tenella sporozoites
0.2 ml of PBS(-) solution containing 330,000 sporozoites of Eimeria brunetsutei
A mixture of 0.2 ml of PBS (-) solution, 0.2 ml of Escherichia coli suspension, 0.2 ml of live Newcastle disease vaccine (33 doses), and 0.2 ml of test plasma Samples (1), (2), (3), (4) The preparation methods for the sample plasma, Eimeria tenella sporozoites, Eimeria brunettii sporozoites, Escherichia coli suspension, and live Newcastle disease vaccine used in () and (5) are as follows. Test plasma was prepared in the same manner as in Example 1. The Eimeria tenella sporozoites used in samples (1) and (5) were prepared as follows. The feces, cecal wall, and cecal contents of chickens to which mature oocysts of Eimeria tenella were orally administered were collected;
Suspended in 3% potassium dichromate solution and
The cells were cultured at 28°C for 2 days. The resulting solution containing mature oocysts is centrifuged (3000 rpm, 10 minutes) and the precipitate is collected. The precipitate is then washed with water and saturated brine is added. Centrifuge this solution (3000 rpm, 10 minutes), remove the supernatant,
The supernatant is diluted with water, the diluted solution is further centrifuged (1000 rpm, 3 minutes) and the precipitate is collected. This precipitate consists almost exclusively of oocysts. Water and a 5% sodium hypochlorite solution are added to the oocysts, left for 15 minutes, and then centrifuged (2000 rpm, 3 minutes). The precipitate obtained is washed with water and then ground in a homogenizer. This ground material consists mostly of sporozoites. The sporozoites are added with 5% chicken bile and 0.25% trypsin in PBS (-) and digested in a 40°C bath for 1.5 hours. The resulting digestive fluid was centrifuged to collect the precipitate, and this precipitate was added to PBS.
(-) Wash with solution. This substance consists mostly of sporozoites. A PBS(-) solution was added to this. The sporozoites of Eimeria brunettii used in samples (2) and (5) are prepared according to the above-mentioned method for preparing sporozoites of Eimeria tenella. However, instead of Eimeria tenera, use Eimeria Brunetstei. The preparation method for E. coli used in samples (3) and (5) is as follows. Escherichia coli isolated from the liver of a chicken with Escherichia coli sepsis was cultured at 37°C using Heart Infusion Broth (manufactured by Difco Laboratory). After culturing for 18 hours, centrifugation is performed at 10,000 rpm for 20 minutes to obtain wet E. coli cells. This was suspended in a required amount of PBS(-) solution so that 1×10 11 E. coli bacteria were added to obtain an E. coli suspension. The method for preparing the live Newatus disease vaccine used in samples (4) and (5) was to add 33 doses of desiccated prophylactic solution to the specified amount of the solution for dissolving the Newkatsul disease live vaccine manufactured by Chemo-Serotherapy Research Institute. It was prepared by dissolving it in There was no problem in preventing leukocytozoonosis when any of the samples (1) to (5) were used.

Claims (1)

【特許請求の範囲】[Claims] 1 ロイコチトゾーン・カウレリに感染した鶏か
ら得られた原虫代謝産物たる蛋白抗原を含有する
血液またはその画分を鶏の総排泄腔に接種するこ
とを特徴とする、鶏ロイコチトゾーン症の予防
法。
1. Prevention of chicken leucocytozoonosis, characterized by inoculating into the cloaca of chickens blood or a fraction thereof containing protein antigens, which are protozoal metabolites, obtained from chickens infected with Leukocytozoon cauleri Law.
JP4607381A 1981-03-27 1981-03-27 Prevention of leucocytozoonosis Granted JPS57159720A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4607381A JPS57159720A (en) 1981-03-27 1981-03-27 Prevention of leucocytozoonosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4607381A JPS57159720A (en) 1981-03-27 1981-03-27 Prevention of leucocytozoonosis

Publications (2)

Publication Number Publication Date
JPS57159720A JPS57159720A (en) 1982-10-01
JPH0220614B2 true JPH0220614B2 (en) 1990-05-10

Family

ID=12736810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4607381A Granted JPS57159720A (en) 1981-03-27 1981-03-27 Prevention of leucocytozoonosis

Country Status (1)

Country Link
JP (1) JPS57159720A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI348376B (en) * 2002-02-26 2011-09-11 Wyeth Corp Selection of poultry eimeria strains through extra-intestinal sporozites

Also Published As

Publication number Publication date
JPS57159720A (en) 1982-10-01

Similar Documents

Publication Publication Date Title
Vetvicka et al. β-Glucan and parasites
JPH08500589A (en) Astragalus Polysaccharide Immunomodulator
James et al. The influence of adjuvant on induction of protective immunity by a non-living vaccine against schistosomiasis.
JPS6354692B2 (en)
EP1713491A1 (en) Simarouba amara and/or momordica charantia extracts for the treatment of coccidiosis in poultry
CN105688206B (en) Periostracum cicadae polysaccharide is preparing the purposes in chicken immune Contrast agent
Clarkson Immunological responses to Histomonas meleagridis in the turkey and fowl.
JP2002012552A (en) Immune activation-adjusting agent for human and animal, and method for preventing and treating infectious disease, skin disease and cancer of human and animal
US10688120B2 (en) Allergy vaccine composition
JPH0220614B2 (en)
US4180627A (en) Process for in vivo transfer of cell-mediated immunity in mammals with alcoholic precipitates of Bovine Transfer factor
US20040142047A1 (en) Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof
CN111569059B (en) Antigen-antibody complex vaccine for poultry and preparation method thereof
CN103491971A (en) Formulation against leishmaniasis and use thereof
EP0037441A1 (en) Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein
US4837018A (en) Vaccines for fowl colibacillosis
Aitken et al. Observations on the serological and dermal responses of turkeys to a single subcutaneous inoculation of inactivated Newcastle disease vaccine in mineral oil adjuvant
JPH0314004B2 (en)
RU2000800C1 (en) Method for production of licorice root extract
JPH0222734B2 (en)
JP2011026241A (en) Vaccine and method for producing the same
JP7246592B2 (en) Method for producing innate immunity activator
WO2000032212A1 (en) Lak activity potentiator orginating in shiitake mushroom hyphae extract and lak activity potentiating preparations containing the same
JPH02288835A (en) Anti-coccidium agent
JPS625132B2 (en)